Vasodilator therapy in chronic congestive heart failure.
Vasodilator agents are relatively new additions to the armamentarium for the management of patients with congestive heart failure. Myocardial failure, irrespective of the aetiology, tends to create a vicious cycle characterised by reduced cardiac output and elevated systemic vascular resistance, which further decrease cardiac output by increasing left ventricular ejection impedance. The rationale for the use of vasodilators is to interrupt the vicious cycle by decreasing the left ventricular ejection impedance by peripheral vasodilatation. Although most vasodilator agents produce qualitatively similar haemodynamic responses, quantitatively their haemodynamic effects differ considerably. Knowledge of the haemodynamic effects of the various vasodilators helps in the selection of a particular drug for the management of such patients. This article reviews the mechanisms of action, haemodynamic effects, pharmacokinetics, clinical usage and adverse effects of non-parenteral vasodilator agents currently available for the management of patients with chronic heart failure.
D002216:Captopril / Q000627:therapeutic use; D002908:Chronic Disease; D004359:Drug Therapy, Combination; D006333:Heart Failure / Q000188:drug therapy* / Q000503:physiopathology; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D006830:Hydralazine / Q000627:therapeutic use; D008914:Minoxidil / Q000627:therapeutic use; D009566:Nitrates / Q000627:therapeutic use; D010879:Piperazines / Q000627:therapeutic use; D014665:Vasodilator Agents / Q000145:classification / Q000627:therapeutic use*
D009566:Nitrates; D010879:Piperazines; D014665:Vasodilator Agents; D006830:Hydralazine; C005185:trimazosin; D008914:Minoxidil; D002216:Captopril